Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

Mil Med Res. 2022 Jan 24;9(1):5. doi: 10.1186/s40779-021-00364-x.

Jiang-Yi Wang^#^{1

2

3}, Guo-Peng Yu^#³, Long Li^#³, Guo-Wen Lin^{4

5}, Ding-Wei Ye^{6

7}

¹ Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.
² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
³ Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.
⁴ Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. guowenlin@urocancer.org.
⁵ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. guowenlin@urocancer.org.
⁶ Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. dwyeli@163.com.
⁷ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. dwyeli@163.com.

^# Contributed equally.

No abstract available

Keywords: Metastatic castration-resistant prostate cancer; Overall survival; PSA decline; PSA velocity; Time to PSA progression.

Publication types